CNS Pharmaceuticals

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOUSTON, Sept. 30, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.

CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate, in the Potentially Pivotal Study for the Treatment of Glioblastoma Multiforme (GBM)

HOUSTON, Aug. 13, 2021 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system (CNS), today reported its financial results for the quarter ended June 30, 2021. Additionally, the Company provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer.

CNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Outlook

Mer Telemanagement Solutions

Toughbuilt Industries Inc

These penny stocks pushed up in recent trading; are they worth watching? The post Best Penny Stocks to Buy Right Now?

Best Penny Stocks to Buy Right Now? 3 For Your Your July 2021 List

The stock price of CNS Pharmaceuticals Inc (NASDAQ: CNSP) increased by over 10% pre-market. This is why it happened.

CNSP Stock Increases Over 10% Pre-Market: Why It Happened

VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that CNS Pharmaceuticals Inc. (“CNS”) (NASDAQ:CNSP), the company that licenses the drug candidate Berubicin to WPD for 29 countries mainly in Europe, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational drug, Berubicin, for the treatment of patients with recurrent glioblastoma multiforme (GBM). As previously reported, CNS had also received Orphan Drug Designation from the FDA for Berubicin for the treatment of patients with recurrent GBM.

WPD Pharmaceuticals' Licensor Receives FDA Fast Track Designation for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans

Glioblastoma multiforme, or GBM, may not sound familiar but if you suffer from this aggressive form of brain cancer the prognosis isn't good. Biopharmaceutical company CNS Pharmaceuticals Inc (NASDAQ:CNSP), though, is looking to change that with its powerful chemotherapy drug Berubicin.

CNS Pharmaceuticals is providing hope to those who suffer from one of the deadliest forms of cancer

HOUSTON, July 1, 2021 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided a business update. Recent Highlights Secured an additional $4.7 million in gross proceeds from ATM at average price of $2.32; extending the Company's cash runway to Q2 2022; Granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for lead investigational drug candidate, Berubicin, for the treatment of patients with recurrent GBM; and Commenced enrollment in potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM.

CNS Pharmaceuticals Continues to Execute on Corporate, Clinical and Regulatory Strategies to Drive Berubicin Towards Commercialization for the Treatment of GBM

The stock price of CNS Pharmaceuticals Inc (NASDAQ: CNSP) increased by over 15% during intraday trading this morning. This is why it happened.

CNSP Stock Price Increases Over 15%: Why It Happened

HOUSTON, June 29, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational drug, Berubicin, for the treatment of patients with recurrent glioblastoma multiforme (GBM). As previously reported, the Company has also received Orphan Drug Designation from the FDA for Berubicin for the treatment of patients with recurrent GBM.

FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

HOUSTON, June 17, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that as part of the annual reconstitution of the Russell stock indexes, CNS Pharmaceuticals has been selected to be added to the Russell 2000® Index effective June 25, 2021, after the close of the U.S. equity markets. John Climaco, CEO of CNS Pharmaceuticals, commented "We are pleased to meet this noteworthy milestone and be included in the Russell 2000® Index.

CNS Pharmaceuticals Announces Inclusion in the Russell 2000® Index

CNS Pharmaceuticals Inc (NASDAQ: CNSP) has opened enrollment for its Phase 2 study evaluating its lead candidate, Berubicin, for recurrent Glioblastoma Multiforme (GBM). The company intends to enroll approximately 210 subjects.

CNS Pharmaceuticals Begins Enrollment, Screening Brain Cancer Study With Berubicin

HOUSTON, May 19, 2021 /PRNewswire/ --  CNS Pharmaceuticals, Inc.  (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM. CNS' lead product candidate, Berubicin, is a novel anthracycline and the first anthracycline to cross the blood-brain barrier.

CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin

HOUSTON, May 14, 2021 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system (CNS), today reported its financial results for the quarter ended March 31, 2021. Additionally, the Company provided a clinical update as well as a business outlook.

CNS Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Outlook

HOUSTON, May 11, 2021 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco , Chief Executive Officer of CNS Pharmaceuticals, will present at the Q2 Virtual Investor Summit on Tuesday, May 18 th at 12:30 PM ET.   In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

CNS Pharmaceuticals to Present at the Q2 Virtual Investor Summit

HOUSTON, March 15, 2021 /PRNewswire/ --  CNS Pharmaceuticals, Inc.  (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals will present at the inaugural Emerging Growth Virtual Conference presented by M Vest LLC and Maxim Group LLC. The conference will take place virtually on March 17 th  and 18th and will feature roundtable discussions with C-suite executives moderated by Maxim Research Analysts, fireside chats with live Q&A, and presentations from hundreds of issuers both domestically and internationally.

CNS Pharmaceuticals to Participate in Inaugural Emerging Growth Virtual Conference

CNS Pharmaceuticals Inc's (NASDAQ: CNSP) partner WPD Pharmaceuticals received a favorable opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland, for its planned upcoming Berubicin trial in adults with Glioblastoma Multiforme (GBM) under the WPD-201 Clinical Trial Protocol. CNS has received study level Central IRB Approval from the Central IRB for the CNS-201 Clinical Trial Protocol.

Polish Regulatory Authority Issues Positive Opinion For CNS Pharma's Brain Cancer Candidate

HOUSTON, Feb. 18, 2021 /PRNewswire/ -- WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) ("WPD") and CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and...

WPD and CNS Pharmaceuticals Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study

Amyris

CYREN

Mereo Biopharma Group Plc - ADR

New Gold

Ultragenyx Pharmaceutical

Exela Technologies

Looking for penny stocks to buy? Click for seven that are hot right now and should continue to rise in the future.

7 Penny Stocks on a Tear Right Now and Still Worth Buying

HOUSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc . (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers CNS Pharmaceuticals' recent announcement that the Investigational New Drug (IND) application for its lead product candidate, Berubicin, for the treatment of Glioblastoma Multiforme (GBM) is now approved and in effect as filed with the US Food and Drug Administration (FDA).

CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application

HOUSTON, Dec. 18, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, will host a conference call...

CNS Pharmaceuticals Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin Today at 8:30am ET

HOUSTON, Dec. 17, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced it will...

CNS Pharmaceuticals Announces Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin

HOUSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers CNS Pharmaceuticals' recent submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) for its brain cancer drug, Berubicin, as well as the Company's plans to commence Phase 2 trials during the first quarter of 2021.

CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent Announcements for Glioblastoma Multiforme (GBM) Therapy

HOUSTON, Oct. 9, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the...

CNS Pharmaceuticals Begins Manufacturing of Berubicin in Europe

HOUSTON, Sept.  24, 2020  (GLOBE NEWSWIRE) -- via NetworkWire -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today announced it has selected Image Analysis Group (“IAG”) as the image partner for its upcoming Berubicin clinical trials.

CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin

HOUSTON, Sept. 11, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc.

News for CNS Pharmaceuticals Stock (CNSP)